Skip to main content
STIM
NASDAQ Industrial Applications And Services

Neuronetics Reports Improved Q1 Financials and Major Insurance Policy Expansion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.089
Mkt Cap
$140.551M
52W Low
$0.8
52W High
$4.85
52W Position info
161% above low
Off High info
57% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

STIM has more than doubled off its 52-week low of $0.8.

Summary

Neuronetics reported an 8% increase in Q1 revenue, a reduced net loss, and significantly improved operating cash flow, alongside a key insurance policy expansion that broadens access to its NeuroStar therapy.


Key Events · Earnings and Guidance · STIM

  • Q1 Revenue Growth

    Total revenue increased 8% year-over-year to $34.5 million, driven by a 15% rise in U.S. clinic revenue.

  • Reduced Cash Burn

    Net cash used in operations significantly decreased to $9.4 million, down from $17.0 million in the prior year, indicating improved cash management.

  • Improved Net Loss

    The company reported a net loss of $(10.8) million, or $(0.16) per share, an improvement from $(12.7) million, or $(0.21) per share, in Q1 2025.

  • Expanded Market Access

    Optum/UHC/UBH broadened its policy to allow nurse practitioners to administer NeuroStar Advanced Therapy, expanding access to approximately 34.8 million covered lives across 26 states and Washington, D.C.


Analysis · STIM · Industrial Applications And Services

This 8-K details Neuronetics' first-quarter results, showing positive momentum with an 8% revenue increase and a notable reduction in cash used for operations, which is crucial for a company with a history of losses. The expansion of Optum/UHC/UBH's policy to allow nurse practitioners to administer NeuroStar Advanced Therapy is a significant development, potentially broadening market access to 34.8 million covered lives and accelerating future growth. While the company continues to project negative cash flow from operations for the full year, the improved Q1 performance and strategic policy win suggest a positive trajectory for operational efficiency and market penetration.

At the time of this filing, STIM was trading at $2.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $140.6M. The 52-week trading range was $0.80 to $4.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STIM - Latest Insights

STIM
Aug 04, 2026, 8:00 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $2.16
Real-time Price: $2.41 info
Change: +$0.250 (+12%) info
Market Cap: $165.619M info
STIM
Jul 20, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $2.41 info
Change: +$0.410 (+21%) info
Market Cap: $165.619M info
STIM
May 29, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.54
Real-time Price: $2.41 info
Change: +$0.8713 (+57%) info
Market Cap: $165.619M info
STIM
May 27, 2026, 10:33 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.26
Real-time Price: $2.41 info
Change: +$1.16 (+92%) info
Market Cap: $165.619M info
STIM
May 14, 2026, 8:32 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $2.41 info
Change: +$0.930 (+63%) info
Market Cap: $165.619M info